13 Oct, 2015 Advancement of New Innovations in RNAi Therapeutics: Bis-RNAi and Reversir
We announced advancement of innovations in RNAi therapeutics with presentation of scientific data on two new platform technologies: Bis-RNAiTM and ReversirTM. The Bis-RNAi platform enables simultaneous knockdown of two distinct disease genes using a single, subcutaneously administered molecular entity consisting of two linked siRNAs conjugated to a GalNAc moiety. The Reversir platform enables tailored control of RNAi pharmacology with rapid reversal of target gene silencing effects using GalNAc-conjugated, single-stranded oligonucleotide constructs that are designed to recognize and bind to the complimentary RISC-bound antisense strand of an siRNA.
We believe these new platform technologies greatly expand the universe of opportunities for RNAi therapeutics and could be deployed across both existing and future pipeline programs. We look forward to the advancement of both the Bis-RNAi and Reversir platforms, as we continuously strive to pioneer breakthroughs in RNAi and find new ways to provide patients with the best possible care.